Description: AlzeCure Pharma AB (publ), a pharmaceutical company, develops drug therapies for the treatment of severe diseases and conditions that affect the central nervous system. The company is developing drug candidates based on the NeuroRestore, Alzstatin, and Painless research platforms. Its pipeline drug candidates include ACD856, which is in phase I clinical trial for Alzheimer's disease, sleep disorders, traumatic brain injuries, and Parkinson's disease; ACD857, ACD679, and ACD680 for Alzheimer's disease; ACD440, a TRPV1 antagonist that has completed phase I clinical trial for neuropathic pain; and TrkA-NAM for osteoarthritic pain. The company was founded in 2012 and is based in Huddinge, Sweden.
Home Page: www.alzecurepharma.se
HAelsovAegen 7
Huddinge,
141 57
Sweden
Phone:
46 8 52 80 03 99
Officers
| Name | Title |
|---|---|
| Mr. Martin Jönsson | Chief Exec. Officer |
| Ms. Birgitta Lundvik | Chief Financial Officer |
| Mr. Johan Sandin | Chief Scientific Officer |
| Mr. Pontus Forsell | Head of Research & Discovery |
| Dr. Marta Segerdahl Storck M.D., Ph.D. | Chief Medical Officer |
Exchange: ST
Country: SE
Currency: Swedish krone (kr)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 6.6192 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 14 |